DIN 02453835 — PRALUENT 150 MG
PRALUENT is a solution of Alirocumab marketed by SANOFI-AVENTIS CANADA INC. The full Alirocumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02453835
- Brand name
- PRALUENT
- Active ingredient
- Alirocumab
- Strength
- 150 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- PCSK9 inhibitor (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Alirocumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02547732 | PRALUENT | 300 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED |
| 02453819 | PRALUENT | 75 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED |